Sci4pharma (OPC) Private Limited
About Sci4pharma (OPC) Private Limited
Data last updated:
Sci4pharma (OPC) Private Limited is a one person company based in New Delhi, Delhi, India. It operates in the real estate leasing and property management segment of the real estate sector. It was incorporated on 17 November 2023.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U70200DL2023OPC422678.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by director Hamid Hasan Faridi.
Its last annual general meeting (AGM) was held on 26 August 2024, and its latest financial statements are for the year ended 31 March 2025. The registered office is at F – 19/2 Second Floor, Shaheen Bagh Abul Fazal E, New Delhi, Delhi, India – 110025.
As per the financials filed for FY 2024, the company reported a revenue of ₹10.85 Lakh. For the same year it recorded a net profit of ₹60,696 (net margin 5.6%) and EBITDA of ₹83,428 (EBITDA margin 7.7%).
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Sci4pharma (OPC) Private Limited's registered office is in New Delhi, Delhi.
- Registered AddressF – 19/2 Second Floor, Shaheen Bagh Abul Fazal E, New Delhi, Delhi, India – 110025
- IndustryReal Estate, Real Estate Leasing, Contractual Work
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Sci4pharma is professional, scientific and technical. In detail, this covers management consultancy activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M3 | Management consultancy activities |
To see the full business activity and turnover split of Sci4pharma (OPC) Private Limited, buy the company report.
Financials of Sci4pharma (OPC) Private Limited
FY 2025 filings availableSci4pharma (OPC) Private Limited reported revenue of ₹10.85 Lakh for FY 2024.
Financial Statement Summary
| Metrics | FY 2023-24 |
|---|---|
| Profit and Loss Statement | |
| Revenue from Operations | |
| Other Income | |
| Total Revenue | |
| Cost of Materials Consumed | |
| Employee Benefit Expense | |
| Finance Costs | |
| Depreciation and Amortisation | |
| Other Expenses | |
| Total Expenses | |
| EBITDA | ₹83,428 |
| Profit Before Tax | |
| Tax Expense | |
| Net Profit (PAT) | ₹60,696 |
| Balance Sheet | |
| Share Capital | |
| Reserves and Surplus | |
| Net Worth (Total Equity) | |
| Long-term Borrowings | |
| Short-term Borrowings | |
| Trade Payables | |
| Total Liabilities | |
| Fixed Assets | |
| Investments | |
| Inventories | |
| Trade Receivables | |
| Cash and Bank Balance | |
| Total Assets | |
Financial Ratios
| Metrics | FY 2023-24 |
|---|---|
| Profitability | |
| EBITDA Margin | 7.7% |
| Net Profit Margin | 5.6% |
| Return on Equity (ROE) | |
| Return on Capital Employed (ROCE) | |
| Return on Assets (ROA) | |
| Liquidity and Debt | |
| Current Ratio | |
| Quick Ratio | |
| Debt-to-Equity Ratio | |
| Interest Coverage Ratio | |
| Efficiency and Growth | |
| Asset Turnover | |
| Receivable Days | |
| Payable Days | |
| Inventory Days | |
| Revenue Growth | |
| Net Profit Growth | |
To see the full financial statements and ratios of Sci4pharma (OPC) Private Limited, buy the company report.
Board of directors of Sci4pharma (OPC) Private Limited
Sci4pharma has 1 director on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hamid Hasan Faridi | Director | 17 Nov 2023 | 2 Years 11 Months | Current |
Peer comparison
Sci4pharma (OPC) Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (management consultancy activities), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Prerana Educational Media Private Limited | ₹10.89 Lakh (FY 2025) | 37.0% | Chennai, Tamil Nadu, India | |||
| Fusionpact Technologies Private Limited | ₹10.88 Lakh (FY 2025) | 103.0% | Noida, Uttar Pradesh, India | |||
| Vulture Management Wings Private Limited | ₹10.87 Lakh (FY 2024) | 168.0% | Chennai, Tamil Nadu, India | |||
| Saint Farid Global Private Limited | ₹10.86 Lakh (FY 2025) | -1.0% | Faridkot, Punjab, India | |||
| Riddhi Siddhi Prime Advisors Private Limited | ₹10.85 Lakh (FY 2025) | 72.0% | Jaipur, Rajasthan, India | |||
| Sci4pharma (OPC) Private Limitedthis company | ₹10.85 Lakh (FY 2024) | ₹60,696 | 5.6% | New Delhi, Delhi, India | ||
| Hedweeg Innovations (OPC) Private Limited | ₹10.83 Lakh (FY 2024) | -62.0% | Ahmedabad, Gujarat, India | |||
| I 2 I Workforce Consulting Private Limited | ₹10.82 Lakh (FY 2025) | 8.0% | Chengalpattu, Tamil Nadu, India | |||
| CPD Skill and Technology Private Limited | ₹10.82 Lakh (FY 2024) | -78.0% | Dhanbad, Jharkhand, India | |||
| Allworth Finserve Private Limited | ₹10.82 Lakh (FY 2025) | 343.0% | Lucknow, Uttar Pradesh, India | |||
| Nebulus Consultancy Private Limited | ₹10.81 Lakh (FY 2025) | 0.0% | Bhubaneswar, Odisha, India |
To see the full peer comparison of Sci4pharma (OPC) Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Sci4pharma (OPC) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Sci4pharma (OPC) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Sci4pharma (OPC) Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Sci4pharma (OPC) Private Limited has 1 board change on record since 2023: 1 appointment. The latest: Hamid Hasan Faridi was appointed as Director on 17 Nov 2023.
Frequently asked questions
Sci4pharma is an active company based in New Delhi, Delhi, India. The company works in real estate leasing, within the real estate industry. It was incorporated on 17 November 2023 (3+ years old) and is registered under CIN U70200DL2023OPC422678.
Sci4pharma has 1 current director:
- Hamid Hasan Faridi - Director
The latest financial statements of Sci4pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 26 August 2024. Year-wise statements from FY 2024 are in the company report.
The CIN (Corporate Identification Number) of Sci4pharma is U70200DL2023OPC422678. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sci4pharma was incorporated on 17 November 2023, making it 3+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Sci4pharma by revenue are Prerana Educational Media Private Limited, Fusionpact Technologies Private Limited, Vulture Management Wings Private Limited, Saint Farid Global Private Limited, Riddhi Siddhi Prime Advisors Private Limited and 5 more, all in the same principal business activity (management consultancy activities).
Hamid Hasan Faridi was appointed as Director on 17 Nov 2023.
The registered office of Sci4pharma is at F – 192 Second Floor, Shaheen Bagh Abul Fazal E, New Delhi, Delhi, India – 110025.
Sci4pharma operates in the real estate industry, in the real estate leasing segment.
The compliance status of Sci4pharma is compliant as of 21 August 2026. The company is actively filing with the Registrar of Companies.
Sci4pharma can be reached at its registered office: F – 192 Second Floor, Shaheen Bagh Abul Fazal E, New Delhi, Delhi, India – 110025.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
